Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma

NCT00510471 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: autologous immunoglobulin idiotype-KLH conjugate vaccine

Sponsor

Genitope Corporation